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ABSTRACT
Plasmablastic lymphoma (PBL) commonly presents as a primary (de novo) oral or extraoral mucocutaneous or nodal mass lesion in patients 
with HIV/AIDS. PBL developing as a secondary malignancy at the same location as a pre-existing tumour is extremely rare and has never 
been reported in association with longstanding or recurrent anal condyloma. A Buschke-Löwenstein tumour is a rare gigantic, locally 
destructive condyloma that is usually located in the anogenital region. We report a case of a diagnostically and therapeutically challenging 
PBL that presented as a rapidly enlarging mass underlying a giant condyloma, thereby mimicking a benign Buschke-Löwenstein tumour. 
Clinical suspicion was further masked by the co-presence of fistulae in ano and adjacent abscess pockets at the time of diagnosis. By the 
time of final diagnosis, the lymphoma had disseminated to regional lymph nodes, a month later to pleural cavities and 4 months later to the 
leptomeninges and bilateral kidneys, leading to permanent deferral of chemotherapeutic intervention. 
LEARNING POINTS
• Plasmablastic lymphoma presenting as a secondary tumour in a patient with pre-existing giant anal condyloma has not been reported 
previously in the literature.
• Unusual clinical presentation of a recurrent giant condyloma, especially rapid growth and significant change in physical appearance, 
should kindle a high index of suspicion for a secondary aggressive tumour.
• Plasmablastic lymphoma disseminates early and rapidly, which complicates its response to treatment.
KEYWORDS
Plasmablastic lymphoma, Buschke-Löwenstein like tumor, antiretroviral therapy associated immune reconstitution
CASE DESCRIPTION
A 34-year-old man with a 4-year history of recurrent perianal and anal condylomata refractory to multiple fulgurations (Fig. 1) and 
complicated by recurrent fistulae in ano and abscess formation, was referred to the surgery clinic due to a rapidly enlarging, excruciatingly 
painful perianal mass temporarily relieved by analgesics. He had a past medical history of HIV/AIDS since 2009 that had over the years 
been complicated by multiple opportunistic infections including cryptococcal meningitis, syphilis, tuberculosis and Kaposi’s sarcoma, 
mainly attributable to poor compliance with antiretroviral therapy. On examination, he was found to have a large fungating right perianal 
mass associated with multiple draining fistulae and an adjacent abscess, laterally (Fig. 2). Ano-perineal computerized tomography showed 
a 4.8×11.2×6.3 cm hyperdense enhancing mass in the right perineum. The patient underwent drainage of the abscess and multiple incision 
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biopsies of the mass were taken. Surprisingly, the biopsies revealed a final diagnosis of plasmablastic lymphoma (PBL) underlying a giant 
perianal condyloma (Figs. 3 and 4).
Figure 1. Perianal condyloma shown here in July 2020 after previously recurring 
several times despite multiple fulgurations
Figure 2. Condyloma presenting as a disfiguring fungating mass in November 2020 thus 
mimicking a Buschke-Löwenstein tumor. An associated abscess was found to be the cause 
of induration lateral to the fungating mass. Biopsies of the mass revealed a diagnosis of 
plasmablastic lymphoma.
Figure 3. Histology of plasmablastic lymphoma (involving the dermis, 
right half of image) underlying a giant condyloma (involving the 
epithelial surface, left half of image).
Staging computerized tomography (CT) demonstrated regional adenopathy and biopsies revealed nodal involvement by the same lymphoma. 
The patient was commenced on a chemotherapy regimen (etoposide, prednisolone, Oncovin, cyclophosphamide, hydroxydaunorubicin) 
which was interrupted due to toxicity. A month following the lymphoma diagnosis, he was found to have malignant pleural effusions. Two 
months later he presented with altered mental state and CT of head showed diffuse enhancing foci throughout the calvarium, skull base 
and mandible; leptomeningeal enhancement in the bilateral parieto-occipital sulci; subtle enhancing soft tissue components in the parieto-
occipital and frontal lobes; and a 2 cm mass in the right mandibular ramus consistent with metastatic spread of the patient's lymphoma. 
Additional imaging revealed possible bilateral renal involvement by lymphoma. Cytological studies confirmed central nervous system 
involvement by the same lymphoma. The patient received several doses of Velcade-ifosfamide, carboplatin and etoposide including 
intrathecal chemotherapy which he poorly tolerated due to neutropenia and mucositis. The chemotherapy regimen was switched to Velcade, 
methotrexate and cytarabine, however, it was complicated by tumour lysis syndrome. The patient continued to deteriorate, compelling his 
family’s decision to defer any further lymphoma treatment and opt for comfort measures.
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Figure 4. (A). Hematoxylin and Eosin 
stain shows the tumor to be composed 
of numerous large plasmablasts. (B). 
CD138 immunoperoxidase stain confirms 
the neoplastic cells show plasmacytic 
differentiation. (C). Ki67 immunoperoxidase 
stain shows that the neoplastic cells have 
a high proliferation index consistent with 
a high-grade malignancy. (D). Epstein 
Barr Virus Encoded RNA (EBER) in situ 
hybridization stain shows the neoplastic 
cells to be diffusely positive for Epstein 
Barr Virus. (E-F). The neoplastic cells show 
strong kappa light chain restriction by in 
situ RNA hybridization staining supporting 
their clonal nature. All images taken at 400X 
magnification.
DISCUSSION
Extraoral PBL often presents as a primary mucocutaneous or nodal tumour [1]. Among extraoral locations, the anal locoregion is a more 
common site of presentation than others [2] where it may be associated with fistulae or abscesses. However, extremely uncommon or to 
our knowledge not yet reported, is concurrent presentation of PBL as a secondary neoplasm underlying a primary anal tumour. Here we 
report an unusual presentation of PBL concurrently presenting beneath a pre-existing giant condyloma thereby masquerading as a benign 
tumour and thus evading early clinical suspicion. Likewise, immediately prior to diagnosis, the patient reported rapid enlargement of his anal 
condyloma, however, because similar prior presentations of his condyloma had revealed fistulae, abscess formation and no malignancy, the 
possibility of an aggressive new malignancy was initially not suspected. 
Of note, our patient’s condyloma–PBL mass showed unusual clinical features in the days leading to lymphoma diagnosis. In July 2020, prior 
to fulguration, the condyloma had a typical warty appearance. However, between October and November 2020, the time period leading to 
lymphoma diagnosis, the condyloma presented as a rapidly enlarging, excruciatingly painful indurated mass with a fungating-like appearance, 
thus mimicking a Buschke-Löwenstein tumour. A characteristic feature of Buschke-Löwenstein tumours is their locally destructive nature 
with a relative low risk of malignant transformation [3]. However, Buschke-Löwenstein tumours usually evolve insidiously and retain a typical 
warty appearance. Therefore, this case further shows the value of an in-depth analysis of differences in clinical presentation as an aid to early 
clinical suspicion of malignancy. Early clinical suspicion of an aggressive malignancy is important because it informs appropriate scheduling 
of clinical visits, any indicated surgical interventions and guides timely pathological work-up.
PBL is known to disseminate early and is therefore associated with a dismal prognosis, with a median overall survival averaging 1 year[1,4]. 
It is however reported that HIV patients optimally treated with HAART may have improved overall survival [5]. Likewise, recently it has 
been reported that early diagnosis, and therefore early intervention with chemotherapy, may improve median overall survival by several 
months[6]. Our patient was unfortunate to have had disseminated disease by the time of diagnosis, however, at that time he had an 
undetectable viral load and an estimated absolute CD4 count >300. Thus, it is intriguing that his illness rapidly progressed to the point when 
it was determined there was no further benefit from chemotherapy, 4 months after diagnosis. Notably, 3 months prior to his lymphoma 
diagnosis, the patient achieved the first ever undetectable HIV viral load in 10 years which at that time corresponded to a >2 log reduction 
in viral load (Fig. 5). Therefore, according to Gopal et al., his lymphoma met the criteria for lymphoma immune reconstitution inflammatory 
syndrome, which was shown by the same authors to show relatively poor overall survival when compared with non-immune reconstitution 
inflammatory syndrome lymphoma [7]. Whether immune reconstitution inflammatory syndrome might explain our patient’s rapid evolution 
and dissemination of his lymphoma remains unclear. 
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CONCLUSION
Our case further emphasizes the need to maintain a high index of clinical suspicion for easy-to-overlook secondary malignancies which may 
evolve at the same location as pre-existing benign primary tumours, and for unmasking of malignancies following immune reconstitution in 
HIV/AIDS patients.
Figure 5. A timeline summary of progression from recurrent condylomas to 
development of giant condyloma associated with underlying lymphoma
